4//SEC Filing
OrbiMed Israel GP Ltd. 4
Accession 0000947871-23-000015
CIK 0001534248other
Filed
Jan 4, 7:00 PM ET
Accepted
Jan 5, 4:49 PM ET
Size
11.0 KB
Accession
0000947871-23-000015
Insider Transaction Report
Form 4
Transactions
- Sale
American Depository Shares
2023-01-03$4.51/sh−70,524$318,063→ 2,241,274 total(indirect: See Footnotes) - Sale
American Depository Shares
2023-01-03$3.34/sh−266,376$889,696→ 2,311,798 total(indirect: See Footnotes)
OrbiMed Israel GP Ltd.
10% Owner
Transactions
- Sale
American Depository Shares
2023-01-03$3.34/sh−266,376$889,696→ 2,311,798 total(indirect: See Footnotes) - Sale
American Depository Shares
2023-01-03$4.51/sh−70,524$318,063→ 2,241,274 total(indirect: See Footnotes)
Footnotes (5)
- [F1]Each American Depository Share ("ADS") represents 20 Ordinary Shares of the Issuer.
- [F2]Represents the weighted average sale price of the ADSs sold, ranging from a low of $2.85 to a high of $3.81 per ADS. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of ADSs sold at each separate price.
- [F3]Represents the weighted average sale price of the ADSs sold, ranging from a low of $3.87 to a high of $4.83 per ADS. The Reporting Persons undertake, upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of ADSs sold at each separate price.
- [F4]These ADSs are held of record by OrbiMed Israel Partners Limited Partnership ("OIP"). OrbiMed Israel BioFund GP Limited Partnership ("OrbiMed BioFund") is the general partner of OIP, and OrbiMed Israel GP Ltd. ("OrbiMed Israel GP") is the general partner of OrbiMed BioFund. By virtue of such relationships, OrbiMed BioFund and OrbiMed Israel GP may be deemed to have voting and investment power with respect to the ADSs held directly by OIP and, as a result, may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). OrbiMed Israel GP exercises this investment and voting power through a management committee comprised of Carl L. Gordon and Erez Chimovits, each of whom disclaims beneficial ownership of the shares held by OIP.
- [F5]This report is being jointly filed by OrbiMed BioFund and OrbiMed Israel GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Documents
Issuer
Chemomab Therapeutics Ltd.
CIK 0001534248
Entity typeother
IncorporatedIsrael
Related Parties
1- filerCIK 0001569590
Filing Metadata
- Form type
- 4
- Filed
- Jan 4, 7:00 PM ET
- Accepted
- Jan 5, 4:49 PM ET
- Size
- 11.0 KB